Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.55 |
| ▸ | CNR2 | P34972 | 4/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909047 | 0.91 | CNR1 (0.61) | CNR1CNR2OPRL1KCNH2 | |
| SCHEMBL218037 | 0.89 | CNR1 (0.53) | CNR1CNR2OPRL1KCNH2 | |
| SCHEMBL219701 | 0.88 | CNR1 (0.53) | CNR1CNR2OPRL1KCNH2 | |
| SCHEMBL909117 | 0.82 | CNR1 (0.59) | CNR1CNR2OPRL1KCNH2 | |
| SCHEMBL3255870 | 0.81 | CNR1 (0.58) | CNR1CNR2OPRL1KCNH2 | |
| SCHEMBL3390751 | 0.81 | OPRL1 (0.69) | CNR1CNR2OPRL1KCNH2 | |
| Hydrochloric Acid SCHEMBL908859 | 0.80 | CNR1 (0.57) | CNR1CNR2OPRL1KCNH2 | |
| SCHEMBL3828981 | 0.80 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL3854175 | 0.80 | CNR1 (0.48) | CNR1CNR2OPRL1KCNH2 | |
| SCHEMBL908671 | 0.79 | OPRL1 (0.54) | CNR1CNR2OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088797-B2 | Substituted N-(4-cyano-1H-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | disclosed |
| EP-2108012-A2 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008099076-A2 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT3, PRMT5, PRMT1 | CNR1 8/4885CNR2 11/4885OPRL1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.